<b>Background:</b> Programmed cell death protein 1(PD-1) blockade has become a standard second-line treatment option for patients with advanced non-small cell lung cancer (NSCLC) without a driver gene mutation. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.